Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Stem Cell Culture

Stem Cell Culture

Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...

Embryonic Stem Cells

Embryonic Stem Cells

Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.

Journal of the American College of Cardiology·2023

Same author

Current indications for insertion of rotary pumps revisited.

Global cardiology science & practice·2019

Same author

A Path Forward for Regenerative Medicine.

Circulation research·2018

Same author

Cardiac Ejection Fraction: New Insights About its Dynamic Nature.

Journal of the American College of Cardiology·2018

Same author

Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review.

JAMA cardiology·2018

Same author

Trial of Embryonic Stem Cell-Derived Cardiac Progenitor Cells: An Encouraging Start.

Journal of the American College of Cardiology·2018

Same journal

Predicting Mortality After Percutaneous Coronary Intervention in a Multiethnic Southeast Asian Population: Insights From Machine Learning.

Journal of cardiovascular translational research·2026

Same journal

RE1-Silencing Transcription Factor: an Atheroprotective Regulator in the Vascular Endothelium.

Journal of cardiovascular translational research·2026

Same journal

Correction: A Hidden Indicator of Cardiovascular Health: Serum Gamma-Glutamyl Transferase in Focus.

Journal of cardiovascular translational research·2026

Same journal

ChemoCardioNet: An Explainable Multimodal Transformer for Early Prediction of Chemotherapy-Induced Cardiotoxicity.

Journal of cardiovascular translational research·2026

Same journal

Metabolic Heterogeneity Across Heart Failure Subtypes Defined by Integrative Multi-Omics Analysis.

Journal of cardiovascular translational research·2026

Same journal

The Immediate Impact of Infarct Size on the Systemic Inflammatory Response: IL-6 as Central Mediator Identified through Biomarker and Proteomic Profiling.

Journal of cardiovascular translational research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

Published on: January 25, 2019

Stem cell therapy trials: a call for standardization.

Leslie W Miller¹

¹Cardiology, Washington Hospital Center, 110 Irving Street, NW, Room 1E-11, Washington, DC 20010, USA. leslie.w.miller@medstar.net

Journal of Cardiovascular Translational Research

|June 19, 2010

Summary

This summary is machine-generated.

Clinical cellular therapy trials for cardiovascular disease face standardization challenges. Establishing standardized methods with regulatory bodies is crucial for improving patient care and advancing research in this field.

More Related Videos

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

Related Experiment Videos

Last Updated: Jun 12, 2026

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy

Published on: January 25, 2019

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Human Mesenchymal Stem Cell Processing for Clinical Applications Using a Closed Semi-Automated Workflow

Published on: March 17, 2023

Area of Science:

Cardiovascular Medicine
Regenerative Medicine
Cellular Therapy

Background:

Numerous clinical trials are underway for cardiovascular disease using cellular therapies.
Significant progress in cellular therapy for cardiovascular disease is hindered by a lack of standardized protocols.

Purpose of the Study:

To highlight the need for standardization in cellular therapy for cardiovascular disease.
To advocate for a collaborative approach to develop standardized methods.

Main Methods:

Review of ongoing clinical trials in cardiovascular cellular therapy.
Identification of key areas lacking standardization (e.g., cell isolation, preparation, delivery).

Main Results:

Approximately 25 new clinical cellular therapy trials for cardiovascular disease are active in the US and Europe.
Key challenges identified include inconsistent cell processing, storage, and delivery parameters.

Conclusions:

Standardization of cellular therapy methods is essential for consistent clinical outcomes.
Collaboration between researchers and regulatory agencies, like the FDA, is vital to establish best practices and improve patient care.